Assessment and Modeling of Plasmonic Photothermal Therapy Delivered via a Fiberoptic Microneedle Device Ex Vivo

dc.contributor.authorAkhter, Forhad
dc.contributor.authorManrique-Bedoya, Santiago
dc.contributor.authorMoreau, Chris
dc.contributor.authorSmith, Andrea Lynn
dc.contributor.authorFeng, Yusheng
dc.contributor.authorMayer, Kathryn M.
dc.contributor.authorHood, R. Lyle
dc.date.accessioned2021-12-23T15:06:45Z
dc.date.available2021-12-23T15:06:45Z
dc.date.issued2021-12-10
dc.date.updated2021-12-23T15:06:46Z
dc.description.abstractPlasmonic photothermal therapy (PPTT) has potential as a superior treatment method for pancreatic cancer, a disease with high mortality partially attributable to the currently non-selective treatment options. PPTT utilizes gold nanoparticles infused into a targeted tissue volume and exposed to a specific light wavelength to induce selective hyperthermia. The current study focuses on developing this approach within an ex vivo porcine pancreas model via an innovative fiberoptic microneedle device (FMD) for co-delivering light and gold nanoparticles. The effects of laser wavelengths (808 vs. 1064 nm), irradiances (20–50 mW·mm(−2)), and gold nanorod (GNR) concentrations (0.1–3 nM) on tissue temperature profiles were evaluated to assess and control hyperthermic generation. The GNRs had a peak absorbance at ~800 nm. Results showed that, at 808 nm, photon absorption and subsequent heat generation within tissue without GNRs was 65% less than 1064 nm. The combination of GNRs and 808 nm resulted in a 200% higher temperature rise than the 1064 nm under similar conditions. A computational model was developed to predict the temperature shift and was validated against experimental results with a deviation of <5%. These results show promise for both a predictive model and spatially selective, tunable treatment modality for pancreatic cancer.
dc.description.departmentMechanical Engineering
dc.description.departmentPhysics and Astronomy
dc.identifierdoi: 10.3390/pharmaceutics13122133
dc.identifier.citationPharmaceutics 13 (12): 2133 (2021)
dc.identifier.urihttps://hdl.handle.net/20.500.12588/782
dc.rightsAttribution 4.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectplasmonic photothermal therapy
dc.subjectgold nanorods
dc.subjectfiberoptic microneedle
dc.subjectnear infrared
dc.subjectphotothermal
dc.subjectCOMSOL tissue model
dc.subjectbioheat
dc.subjecthyperthermia
dc.titleAssessment and Modeling of Plasmonic Photothermal Therapy Delivered via a Fiberoptic Microneedle Device Ex Vivo
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pharmaceutics-13-02133.pdf
Size:
3.77 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: